Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,102 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Injectable saline Clear all

Conditions: Mastectomy, Nerve Block, Analgesia, Postoperative
Interventions: Pectoralis block, Normal saline injection, Ropivacaine Injection; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Dysferlinopathy
Interventions: rAAVrh74.MHCK7.DYSF.DV; Drug
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Plantar Fasciitis
Interventions: Corticosteroid injection (CSI) with local anesthetic (LA), Local anesthetic (LA) with Saline injection; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Headache, Cognitive Disturbance, Skin Hyperpigmentation, Arthralgia
Interventions: Calcium DTPA, Zinc DTPA; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Lupus Nephritis
Interventions: Daxdilimab, Placebo (Normal Saline); Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more

Conditions: Pachyonychia Congenita
Interventions: TD101, Normal saline (placebo); Drug
Lead sponsor: Pachyonychia Congenita Project; Other
Eligibility: 10 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Venous Stasis Ulcer, Venous Leg Ulcer
Interventions: MTX-001 (human amniotic fluid); Biological
Lead sponsor: Merakris Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 12
States / cities: Tucson, Arizona • Castro Valley, California • Los Angeles, California + 8 more

Conditions: STEMI, STEMI (ST Elevation MI), STEMI - ST Elevation Myocardial Infarction (MI), Stent Implantation
Interventions: Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once; Drug · Other
Lead sponsor: Implicit Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: St Louis, Missouri • Charlottesville, Virginia

Conditions: Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions: testosterone, clomiphene, placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Ileostomy - Stoma
Interventions: Transversus abdominis plane block; Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Galveston, Texas • Seattle, Washington

Conditions: Fetal Growth Retardation
Interventions: Ferumoxytol infusion, MRI scan; Drug · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Anterior Cruciate Ligament
Interventions: Gel-One, Saline Placebo; Drug · Other
Lead sponsor: Cale Jacobs, PhD; Other
Eligibility: 14 Years to 33 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Knee Osteoarthritis, Knee Rheumatism
Interventions: Obturator nerve regional block, Adductor canal regional block, Saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions: [18F]FTP PET/CT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastroenteritis Escherichia Coli
Interventions: Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more

Conditions: Post-operative Pain
Interventions: Bupivacaine, Botulinum Toxins, Analgesics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Malignant Glioma
Interventions: Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:; Biological
Lead sponsor: Frank Lieberman; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Baker's Cyst
Interventions: Platelets-Rich-Plasma, Corticosteroid; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Virus Diseases
Interventions: Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more

Conditions: Chronic Ischemic Heart Disease, Left Ventricular Dysfunction, Angina, Ischemic Cardiomyopathy
Interventions: Adult stem cells, Placebo; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 5
States / cities: Gainesville, Florida • Minneapolis, Minnesota • Cleveland, Ohio + 2 more

Conditions: Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
Interventions: Hyaluronic Acid (HA), Tranexamic Acid (TXA), Saline (placebo); Procedure · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Effect of Pectoralis Block on Analgesia After Simple Mastectomy

rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Infracalcaneal Peppering Injection Technique for Chronic Plantar Fasciitis

Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

MTX-001 for the Treatment of Non-Healing Venous Stasis Ulcers

Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI

Hypogonadism in Young Men With Type 2 Diabetes

Transversus Abdominis Plane Blocks for Ileostomy Takedown: A Prospective Study

Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector

Placental Lesions in Fetal Growth Restrictions

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions

Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

PRP vs Corticosteroid in Baker's Cyst

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

Effect of TXA on Reducing Bruising After Filler Injection